EOM Pharmaceuticals, Inc. (EOM) and ImmunoCellular Therapeutics, Ltd. have closed on a merger agreement pursuant to which the shareholders of EOM are now the majority shareholders of the combined company. The merger will create a public company that will continue EOM’s focus on advancing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases.
ImmunoCellular will be renamed EOM Pharmaceuticals Holdings, Inc. Pending the assignment of a new ticker symbol, EOM Pharmaceuticals’ Common Stock will continue to be quoted on the OTC Markets under the ticker symbol “IMUC.” EOM may consider in the future changing the principal listing of the Company Common Stock to a national exchange, assuming it will then meet the relevant listing requirements.
To rescue, repair, and restore health in patients suffering
from debilitating and sometimes deadly diseases
Support each other and humankind
EOM Pharmaceuticals’ goal is to rescue, repair, and restore health. We are focused on developing novel drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases.
Rethinking the Role of Immunomodulators
Watch how EOM Pharmaceuticals is rethinking the role of immunomodulators with its novel, dynamically dual-acting, broad-spectrum lead asset, EOM613, which can produce anti- and pro-inflammatory effects and could mitigate a hyperimmune reaction or “cytokine storm.”